CStone RET Inhibitor Approved in China for First-Line Treatment in NSCLC Patients

Suzhou CStone Pharma reported Gavreto® (pralsetinib), a selective rearranged during transfection (RET) inhibitor, was approved as a first-line therapy for China patients with locally advanced or metastatic RET fusion-positive non-small cell lung cancer (NSCLC). Two years ago, Gavreto was approved as a second-line therapy for the indication following platinum chemotherapy, the first RET inhibitor green-lighted in China. The latest milestone was CStone’s eleventh NDA approval in China. In 2018, CStone acquired China rights to the RET inhibitor and two other candidates in a $386 million deal with Blueprint Medicines of Cambridge, Mass. More details....

Stock Symbol: (HK: 2616)

Share this with colleagues: